These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2164430)

  • 21. Vipoma, glucagonoma and the role of Sandostatin.
    Bloom SR
    NATNEWS; 1989 Jul; 26(7):15. PubMed ID: 2550822
    [No Abstract]   [Full Text] [Related]  

  • 22. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An important new treatment for carcinoid tumors and VIPomas.
    Oncology (Williston Park); 1988 Dec; 2(12):35-6. PubMed ID: 2856315
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Attempt in treating benign insulinoma by delayed somatostatin. 2 cases].
    Picq R; Vialettes B; de la Tour d'Auvergne M; Joliot AY; Vague P
    Presse Med; 1988 Nov; 17(39):2087. PubMed ID: 2849769
    [No Abstract]   [Full Text] [Related]  

  • 26. Octreotide: a somatostatin analog.
    Salman K; Rose LI
    Am Fam Physician; 1989 Jun; 39(6):207-11. PubMed ID: 2543196
    [No Abstract]   [Full Text] [Related]  

  • 27. Parathyroid hormone-related protein in hypercalcaemia of malignancy.
    Martin TJ; Suva LJ
    Clin Endocrinol (Oxf); 1989 Nov; 31(5):631-47. PubMed ID: 2697477
    [No Abstract]   [Full Text] [Related]  

  • 28. [Short-term treatment of a VIPoma with somatostatin analogue in advance of curative operation].
    Yoshioka M; Sakazume M; Fukagawa M; Seki T
    Nihon Naika Gakkai Zasshi; 1988 Aug; 77(8):1276-7. PubMed ID: 2853716
    [No Abstract]   [Full Text] [Related]  

  • 29. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
    Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
    Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Patient with hypercalcemia and pancreatic islet cell tumor (parathyrinoma)].
    Romero Pérez JC; Erdozaín Ruiz I; Amérigo García MJ; Perera Molinero A; Romero Candau F; Rosquete González JE
    An Med Interna; 2001 Jun; 18(6):339-40. PubMed ID: 11503587
    [No Abstract]   [Full Text] [Related]  

  • 31. A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor.
    Pathak RD; Tran TH; Burshell AL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):581-4. PubMed ID: 14764765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical use of the somatostatin analog SMS 201-995 in endocrinology.
    Cozzi R; Liuzzi A; Dallabonzana D; Oppizzi G; Orlandi P; De Palo C; Petroncini MM; Piolini M; Chiodini PG
    J Endocrinol Invest; 1988 Nov; 11(10):737-40. PubMed ID: 2852695
    [No Abstract]   [Full Text] [Related]  

  • 33. Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia.
    Miraliakbari BA; Asa SL; Boudreau SF
    Hum Pathol; 1992 Aug; 23(8):884-7. PubMed ID: 1322859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic islet-cell neoplasia, with secretion of a parathormone-like substance and hypercalcemia.
    Vair DB; Boudreau SF; Reid EL
    Can J Surg; 1987 Mar; 30(2):108-10. PubMed ID: 3030525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1.
    Milanesi A; Yu R; Geller SA; Burton D; Deftos LJ; Wolin EM
    Pancreas; 2011 May; 40(4):634-7. PubMed ID: 21483254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of a parathyroid hormone analogue in the pathogenesis of malignant hypercalcemia].
    Rizzoli R; Buchs B; Pizurki L; Caverzasio J; Sappino AP; Vadas L; Arlot M; Bonjour JP
    Pathol Biol (Paris); 1990 Jun; 38(6):656-64. PubMed ID: 2197594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone-related protein mediates hypercalcemia in an exocrine pancreatic cancer.
    Tachibana I; Nakano S; Akiyama T; Ogami Y; Tabaru A; Otsuki M
    Am J Gastroenterol; 1994 Sep; 89(9):1580-1. PubMed ID: 8079945
    [No Abstract]   [Full Text] [Related]  

  • 38. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.
    Saltz L; Trochanowski B; Buckley M; Heffernan B; Niedzwiecki D; Tao Y; Kelsen D
    Cancer; 1993 Jul; 72(1):244-8. PubMed ID: 8389666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin analogue SMS 201-995 long term therapy for vipoma.
    Juby LD; Burke DA; Axon AT
    Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Malignant hypercalcemia with and without bone metastasis].
    Millán Núñez-Cortés J; de Moneo González A
    Rev Clin Esp; 1996 Jun; 196(6):388-91. PubMed ID: 8767075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.